Literature DB >> 19237554

Directed evolution of adeno-associated virus to an infectious respiratory virus.

Katherine J D A Excoffon1, James T Koerber, David D Dickey, Matthew Murtha, Shaf Keshavjee, Brian K Kaspar, Joseph Zabner, David V Schaffer.   

Abstract

Respiratory viruses evolve to maintain infectivity levels that permit spread yet prevent host and virus extinction, resulting in surprisingly low infection rates. Respiratory viruses harnessed as gene therapy vectors have illustrated this limitation. We used directed evolution in an organotypic human airway model to generate a highly infectious adeno-associated virus. This virus mediated gene transfer more than 100-fold better than parental strains and corrected the cystic fibrosis epithelial Cl(-) transport defect. Thus, under appropriate selective pressures, viruses can evolve to be more infectious than observed in nature, a finding that holds significant implications for designing vectors for gene therapy and for understanding emerging pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237554      PMCID: PMC2646629          DOI: 10.1073/pnas.0813365106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect.

Authors:  G Wang; V Slepushkin; J Zabner; S Keshavjee; J C Johnston; S L Sauter; D J Jolly; T W Dubensky; B L Davidson; P B McCray
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.

Authors:  R W Walters; S M Yi; S Keshavjee; K E Brown; M J Welsh; J A Chiorini; J Zabner
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

4.  CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo.

Authors:  Lynda S Ostedgaard; Joseph Zabner; Daniel W Vermeer; Tatiana Rokhlina; Philip H Karp; Arlene A Stecenko; Christoph Randak; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

5.  A viral phospholipase A2 is required for parvovirus infectivity.

Authors:  Z Zádori; J Szelei; M C Lacoste; Y Li; S Gariépy; P Raymond; M Allaire; I R Nabi; P Tijssen
Journal:  Dev Cell       Date:  2001-08       Impact factor: 12.270

6.  Identification of PDGFR as a receptor for AAV-5 transduction.

Authors:  Giovanni Di Pasquale; Beverly L Davidson; Colleen S Stein; Inês Martins; Dominic Scudiero; Anne Monks; John A Chiorini
Journal:  Nat Med       Date:  2003-09-14       Impact factor: 53.440

7.  Interfacial enzymology of parvovirus phospholipases A2.

Authors:  Stéphane Canaan; Zoltán Zádori; Farideh Ghomashchi; James Bollinger; Martin Sadilek; Marie Eve Moreau; Peter Tijssen; Michael H Gelb
Journal:  J Biol Chem       Date:  2004-01-15       Impact factor: 5.157

8.  Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.

Authors:  Oliver J Müller; Felix Kaul; Matthew D Weitzman; Renata Pasqualini; Wadih Arap; Jürgen A Kleinschmidt; Martin Trepel
Journal:  Nat Biotechnol       Date:  2003-08-03       Impact factor: 54.908

9.  Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia.

Authors:  Ziying Yan; Roman Zak; Yulong Zhang; Wei Ding; Simon Godwin; Keith Munson; Richard Peluso; John F Engelhardt
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Structure of adeno-associated virus serotype 5.

Authors:  Robert W Walters; Mavis Agbandje-McKenna; Valorie D Bowman; Thomas O Moninger; Norman H Olson; Michael Seiler; John A Chiorini; Timothy S Baker; Joseph Zabner
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  82 in total

1.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Polarized AAVR expression determines infectivity by AAV gene therapy vectors.

Authors:  Bradley A Hamilton; Xiaopeng Li; Alejandro A Pezzulo; Mahmoud H Abou Alaiwa; Joseph Zabner
Journal:  Gene Ther       Date:  2019-04-08       Impact factor: 5.250

Review 3.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 4.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

5.  Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.

Authors:  Lynda S Ostedgaard; David K Meyerholz; Daniel W Vermeer; Philip H Karp; Lindsey Schneider; Curt D Sigmund; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-01       Impact factor: 11.205

6.  Hoechst increases adeno-associated virus-mediated transgene expression in airway epithelia by inducing the cytomegalovirus promoter.

Authors:  David D Dickey; Katherine J D A Excoffon; Krista R Young; Kalpaj R Parekh; Joseph Zabner
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.565

7.  Capsid antibodies to different adeno-associated virus serotypes bind common regions.

Authors:  Brittney L Gurda; Michael A DiMattia; Edward B Miller; Antonette Bennett; Robert McKenna; Wendy S Weichert; Christian D Nelson; Wei-jun Chen; Nicholas Muzyczka; Norman H Olson; Robert S Sinkovits; John A Chiorini; Sergei Zolotutkhin; Olga G Kozyreva; R Jude Samulski; Timothy S Baker; Colin R Parrish; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

8.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

9.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.

Authors:  Wuping Li; Liqun Zhang; Jarrod S Johnson; Wu Zhijian; Joshua C Grieger; Xiao Ping-Jie; Lauren M Drouin; Mavis Agbandje-McKenna; Raymond J Pickles; R Jude Samulski
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.